DSAM Partners’s Precision BioSciences DTIL Stock Holding History

DSAM Partners’s Portfolio DTIL Stock Details DTIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-19,705	Closed	-$4.96M	–	60
2019 Q3	$4.96M	Hold	19,705	–	–	0.93%	29
2019 Q2	$7.83M	Buy	19,705 +17,205	+688%	+$6.93M	0.97%	38
2019 Q1	$1.35M	Buy	+2,500	New	+$1.33M	0.19%	53

Other funds holding DTIL

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

ACWM

Adams Chetwood Wealth Management Durham, North Carolina $176M AUM 8.48% 1-Year Est. Return

DSAM Partners's DTIL Position: Q4 2019 in Review

DSAM Partners sold out of Precision BioSciences (DTIL) in Q4 2019, closing a stake of 19,705 shares — an estimated $4.96M sold.

DSAM Partners first reported a position in DTIL in Q1 2019 and held it in 3 quarters. The position peaked at $7.83M in Q2 2019. 95 funds tracked by Wall St. Rank hold DTIL as of Q4 2019.

DSAM Partners reported no remaining Precision BioSciences position as of Q4 2019 after selling out during the quarter.
DSAM Partners sold 19,705 Precision BioSciences shares in Q4 2019, an estimated $4.96M.
DSAM Partners first reported a position in Precision BioSciences in Q1 2019 and held it in 3 quarters.
DSAM Partners's Precision BioSciences position peaked at $7.83M in Q2 2019.
95 funds tracked by Wall St. Rank held Precision BioSciences as of Q4 2019.

Based on DSAM Partners's 13F filing for Q4 2019, filed 14 Feb 2020.